The U.S. Food and Drug Administration (FDA) has approved Sunharbo (asundexian) 50 mg tablets as the first factor XIa inhibitor. This medication is authorized for use in combination with antiplatelet therapy to reduce the risk of stroke in specific adult populations.

The approval targets adults who have recently experienced a mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack. Sunharbo offers a new therapeutic option in the management of secondary stroke prevention.

Clinicians managing secondary stroke risk and antithrombotic treatment regimens may consider Sunharbo for appropriate patients. This development reflects ongoing efforts to improve outcomes in stroke care through innovative pharmacological interventions.